Morgan Stanley Cuts Edwards Lifesciences Corporation (EW) Price Target to $120.00

Adjust Comment Print

Cohen Lawrence B decreased Edwards Lifesciences Corp (EW) stake by 13.99% reported in 2017Q2 SEC filing. Alexandria Capital LLC boosted its stake in shares of Edwards Lifesciences Corporation by 1.7% in the 2nd quarter. The company is expected to announce its next earnings report on Wednesday, February 7th. UBS initiated the shares of EW in report on Tuesday, September 22 with "Buy" rating. During the same period in the prior year, the business posted $0.68 EPS. analysts expect that Edwards Lifesciences Corporation will post 3.75 EPS for the current fiscal year. RBC Capital Markets maintained Edwards Lifesciences Corp (NYSE:EW) rating on Wednesday, October 26. More interesting news about Edwards Lifesciences Corp (NYSE:EW) were released by: and their article: "Cramer's lightning round: I'm a buyer of Edwards Lifesciences despite the ..." published on October 31, 2017 as well as's news article titled: "Edwards SAPIEN 3 Transcatheter Valve Demonstrates Significant Cost Savings ..." with publication date: October 31, 2017. The medical research company reported $0.84 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.86 by ($0.02). Edwards Lifesciences Corporation had a net margin of 22.47% and a return on equity of 27.22%. Edwards Lifesciences Corp. The business had revenue of $739.40 million for the quarter, compared to the consensus estimate of $749.14 million. During the same period a year ago, the company earned $0.68 EPS. The company's revenue for the quarter was up 20.1% on a year-over-year basis.

Several brokerages have weighed in on EW. On October 25 Canaccord Genuity kept the stock rating at "Buy" with a current price target of $135.00.

Equity analyst SunTrust Banks issued a report on EW with a rating of "Buy" and projecting a price target of $124.00. Bank of America Corporation increased their price target on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a "buy" rating in a research report on Thursday, July 27th.

The average Wall Street analyst rating for Edwards Lifesciences Corporation is Strong Buy, according to the average of 15 analyst scores. Company insiders own 2.13% of the company's stock. The stock has an average rating of "Buy" and an average price target of $125.17. If you are viewing this article on another website, it was stolen and reposted in violation of USA and global copyright & trademark law. The legal version of this news story can be read at Winslow Evans & Crocker Inc who had been investing in Edwards Lifesciences Corp for a number of months, seems to be bullish on the $21.98 billion market cap company. Finally, William Blair reissued an "outperform" rating on shares of Edwards Lifesciences Corporation in a research report on Monday, August 28th. The shares were sold at an average price of $100.93, for a total transaction of $3,320,597.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Larry L. Wood sold 18,960 shares of the firm's stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $111.81, for a total transaction of $2,119,917.60. The disclosure for this sale can be found here. Sigma Planning Corp now owns 2,609 shares of the medical research company's stock valued at $260,000 after buying an additional 31 shares during the period.

A number of large investors have recently added to or reduced their stakes in the stock. The institutional investor owned 62,289 shares of the medical research company's stock after acquiring an additional 48,075 shares during the period. Koch Industries Inc. now owns 1,397,254 shares of the medical research company's stock valued at $1,386,000 after buying an additional 1,392,345 shares during the last quarter. Wendell David Associates Inc. acquired a new position in shares of Edwards Lifesciences Corporation during the second quarter worth about $316,000. Institutional investors and hedge funds own 82.69% of the company's stock. Nisa Investment Advisors LLC boosted its position in shares of Edwards Lifesciences Corporation by 28.7% during the second quarter. Finally, Oregon Public Employees Retirement Fund grew its holdings in Edwards Lifesciences Corporation by 7.1% during the third quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company's stock valued at $136,000 after purchasing an additional 19 shares in the last quarter. The Company manufactures heart valve systems and fix products used to replace or fix a patient's diseased or defective heart valve.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients.